http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#Head
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#assertion
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#provenance
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#pubinfo
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#assertion
http://purl.obolibrary.org/obo/DOID_1184
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_1184
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00860
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#association
http://www.w3.org/2000/01/rdf-schema#label
prednisolone syrup prednisolone oral solution usp is indicated in the following conditions 1 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2 rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3 collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus acute rheumatic carditis 4 dermatologic diseases pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevens johnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis 5 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis bronchial asthma contact dermatitis atopic dermatitis serum sickness drug hypersensitivity reactions 6 ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia allergic conjunctivitis keratitis chorioretinitis optic neuritis iritis and iridocyclitis 7 respiratory diseases symptomatic sarcoidosis loeffler s syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy aspiration pneumonitis 8 hematologic disorders idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia 9 neoplastic diseases for palliative management of leukemias and lymphomas in adults acute leukemia of childhood 1 edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 11 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis 12 miscellaneous tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement in addition to the above indications prednisolone syrup prednisolone oral solution usp is indicated for systemic dermatomyositis polymyositis
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/SymptomaticReliefIndication
https://identifiers.org/drugbank:DB00860
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#provenance
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#pubinfo
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#sig
http://purl.org/nanopub/x/hasSignature
TlEUbFe75l22zY7EgsZdNc1j1UpjoMcs150AFS6CaDKlSk8SP+ata7R2hVmE2+ba0U8TyBjEMYYV+7WrZVDFQDmn3zwQAK2vJfWTFs/HDa7xwH2P5sNT93Lx0ROirSgGo8x0VflFA3NQCeTJ+uCmKvHid0qcpmTFkRx0sor286I=
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ
http://purl.org/dc/terms/created
2021-06-13T15:10:25.938+02:00
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA4swZXIoCPr5RwDSxRP9WLEWE6qPHvDu_K8ACCtgW7YQ
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs